Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemoradiotherapy vs Chemoradiotherapy Alone in Muscle-invasive Bladder Cancer
NCT04241185Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2020
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Merck & Co. Primary endpoint: Bladder Intact Event-Free Survival. Started May 2020; status: active, not recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04241185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241185.